TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05858021

Intervention type: DIAGNOSTIC_TEST
Intervention: Physical examination
Description: Per participant, two colorectal surgeons, will separately and consecutively each perform disease assessment in accordance with the 'usual' clinical approach (direct visualisation with 'naked eye') with the exception that for each lesion identified they will undertake a series of measurements, obtain photographs of each lesion and record their findings on the proforma provided.~Once all lesions identified have been recorded diagrammatically and photographically, EP and PM will confer and collate lesions of suspicion for biopsy. All lesions suspicious for aHSIL will be biopsied/excised in keeping with usual care.~During the study period we anticipate HRA to become available within the LTHTR and incorporated into usual care for the clinical assessment of patients with aHSIL. HRA will be used in addition to direct visualisation such that 'usual care' comprises clinical assessment with direct visualisation and HRA.
Study: NCT05551715

Intervention type: DEVICE
Group type: OTHER
Intervention: Software development for individualized refractive surgery
Description: Software development for individualized refractive surgery

Intervention type: DEVICE
Group type: OTHER
Intervention: Software development for individualized refractive surgery
Description: Software development for individualized refractive surgery

Intervention type: DEVICE
Group type: OTHER
Intervention: Software development for individualized refractive surgery
Description: Software development for individualized refractive surgery
Study: NCT05888090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone, right lateral, and semi-elevated supine positions
Description: Each participant will be followed during three feedings and the prone, right lateral, and semi-elevated supine positions will be applied once.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi-elevated supine, prone, and right lateral positions
Description: Each participant will be followed during three feedings and the semi-elevated supine, prone, and right lateral positions will be applied once.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Right lateral, semi-elevated supine, and prone positions
Description: Each participant will be followed during three feedings and the right lateral, semi-elevated supine, and prone positions will be applied once.
Study: NCT06209554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasonic tips and Gracey curettes, airflow with erythritol and diode laser
Description: diode laser and erythritol used as adjunctive method in the treatment of periodontitis in addition to scaling and root planning

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasonic tips and Gracey curettes, airflow with erythritol and diode laser
Description: diode laser and erythritol used as adjunctive method in the treatment of periodontitis in addition to scaling and root planning

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasonic tips and Gracey curettes, airflow with erythritol and diode laser
Description: diode laser and erythritol used as adjunctive method in the treatment of periodontitis in addition to scaling and root planning
Study: NCT05795686

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of program AVanCer
Description: Evaluation of program AVanCer with quantitative and qualitative approaches
Study: NCT05382247

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonography
Description: Full history taking, thorough clinical examination, review of participants medical files.~Patients will be typically examined during spontaneous respiration to help assessement of diaphragmatic motion.~The supine position will be used whenever possible to avoid overall variability, side-to-side variability, and for greater reproducibility.~Patients can be examined in quiet respiration and during deep breathing or sniff maneuver.~For uncooperative patients appropriate sedative for age will be used. Assessement of diaphragmatic function: the analysis of the dome excursion with M mode approach Evaluation of diaphragmatic thickness and thickening during inspiration by analyzing the apposition zone.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonography
Description: Full history taking, thorough clinical examination, review of participants medical files.~Patients will be typically examined during spontaneous respiration to help assessement of diaphragmatic motion.~The supine position will be used whenever possible to avoid overall variability, side-to-side variability, and for greater reproducibility.~Patients can be examined in quiet respiration and during deep breathing or sniff maneuver.~For uncooperative patients appropriate sedative for age will be used. Assessement of diaphragmatic function: the analysis of the dome excursion with M mode approach Evaluation of diaphragmatic thickness and thickening during inspiration by analyzing the apposition zone.
Study: NCT05442151

Intervention type: DRUG
Group type: OTHER
Intervention: PET/CT ([F-18]FAPI-74)
Description: PET/CT using \[18F\] FAPI-74 injection
Study: NCT05487898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycling wheelchair
Description: Apply the mechanical principle of pedaling on a bicycle to a conventional wheelchair
Study: NCT05280028

Intervention type: DRUG
Intervention: Tibolone 2.5 mg
Description: Tibolone 2.5 mg per day

Intervention type: DRUG
Intervention: Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg
Description: Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg per day
Study: NCT06229106

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Symfony IOL
Description: The Symfony IOL is a lens designed to provide high quality vision up tp 26 inches reducing the need for glasses after routine cataract surgery in patients with or without astigmatism.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vivity IOL
Description: The Vivity IOL is a lens that provides extended range of vision ranging from distance to near reducing the need for glasses after routine cataract surgery in patients with or without astigmatism.
Study: NCT06443918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Just-in-Time Adaptive Intervention for Child and Family Mental Health
Description: Families in the intervention group will download an app on their smartphones. The app will deliver psychoeducational modules and family-based homework activities. It will include a component where AI is used to assess the quality of family-based interactions and provide in-the-moment feedback and coaching to guide the family interaction.
Study: NCT06031649

Intervention type: DEVICE
Intervention: MyotonPRO device
Description: It is a valid and reliable device for measuring the muscular mechanical properties

Intervention type: DEVICE
Intervention: MyotonPRO device
Description: It is a valid and reliable device for measuring the muscular mechanical properties
Study: NCT06244160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High flow oxygen therapy
Description: High flow oxygen therapy delivered via nasal cannulae, at 50 litres flow with variable oxygen levels
Study: NCT04743921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reparel Knee Sleeve
Description: Patients who are recommended for non-operative management of knee osteoarthritis and have been consented in clinic to participate in the study will be given a Reparel™ knee sleeve to wear for knee osteoarthritis management. Each device will be numbered and recorded in the patient's REDCap entry for future reference if needed. Following administration of the Reparel™ knee sleeve, patients will be given instructions on how to use/wear the sleeve while performing activities of daily living or sports that had previously resulted in knee pain and also be asked to do the follows: wear the sleeve as much as they possibly can; not change their usual activities and diet during the time they are on this study; record in a diary the number of hours sleeve was worn per day; record any adverse eﬀects or discomfort due to sleeve use; refrain from altering treatment for knee osteoarthritis.
Study: NCT06185621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg aspirin
Description: Patients received oral 100mg aspirin, one tablet daily for 2 years
Study: NCT05856916

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: Creatine monohydrate will be self-administered by an oral route at a dose of 5g/day in powdered form. Administration will begin on Study Day 1 and continue for 10 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (in the form of lactose) will be self-administered by an oral route at a dose of 5g/day in powdered form. Administration will begin on Study Day 1 and continue for 10 weeks.
Study: NCT06039462

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Application of a virtual reality headset
Description: Use of a headset to experience a different reality
Study: NCT06198803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L Carnitine
Description: The study population will be randomly divided into 2 groups, 1 group will receive Carnitine supplementation in a dose of 100mg/kg/day
Study: NCT05911659

Intervention type: DRUG
Intervention: Ticagrelor
Description: Patients with acute coronary syndromes undergo primary PCI and administered 180 mg loading dose ticagrelor before PCI

Intervention type: DRUG
Intervention: Ticagrelor
Description: Patients with acute coronary syndromes undergo primary PCI and administered 180 mg loading dose ticagrelor before PCI

Intervention type: DRUG
Intervention: Ticagrelor
Description: Patients with acute coronary syndromes undergo primary PCI and administered 180 mg loading dose ticagrelor before PCI

Intervention type: DRUG
Intervention: Ticagrelor
Description: Patients with acute coronary syndromes undergo primary PCI and administered 180 mg loading dose ticagrelor before PCI
Study: NCT05015192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NH102
Description: tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NH102
Description: tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NH102
Description: tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NH102
Description: tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NH102
Description: tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NH102
Description: tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablets, orally
Study: NCT06015139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cotton roll-coated viscoelastic polymer pads
Description: relton-hall frame cotton roll-coated viscoelastic polymer pads

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: viscoelastic polymer pads
Description: relton-hall frame viscoelastic polymer pads
Study: NCT06491108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vardenafil 5 Mg Oral Tablet
Description: Comparing safety and efficacy of Vardenafil 5 mg twice oral daily versus established drugs e.g.Tadalafil 5mg and Tamsulosin 0.4 mg once oral daily in terms of (voiding function, sexual function and quality of life) in the management of moderate BPH related LUTS (benign prostatic hyperplasia related lower urinary tract syptoms )

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vardenafil 5 Mg Oral Tablet
Description: Comparing safety and efficacy of Vardenafil 5 mg twice oral daily versus established drugs e.g.Tadalafil 5mg and Tamsulosin 0.4 mg once oral daily in terms of (voiding function, sexual function and quality of life) in the management of moderate BPH related LUTS (benign prostatic hyperplasia related lower urinary tract syptoms )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil 5 Mg Oral Tablet
Description: Comparing safety and efficacy of Vardenafil 5 mg twice oral daily versus established drugs e.g.Tadalafil 5mg and Tamsulosin 0.4 mg once oral daily in terms of (voiding function, sexual function and quality of life) in the management of moderate BPH related LUTS (benign prostatic hyperplasia related lower urinary tract syptoms )
Study: NCT02043821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 14days

Intervention type: OTHER
Group type: OTHER
Intervention: placebo
Description: 14 days
Study: NCT05060653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SBRT followed by surgical stabilization within 24-48 hours
Description: In a first step, patients will undergo SBRT with active sparing of the surgical site. Patients will receive high dose, single to few fractions radiotherapy consisting of a boost to the metastases exclusively. The bony compartment containing the metastatic lesion will receive an elective dose in order to treat subclinical disease. Treatment planning is performed on the pre-treatment CT and MRI data in radiotherapy position that are mutually registered to yield information on all relevant structures for planning. Dose constraints are set for the organ at risks based on institution specific guidelines. All patients will be treated with on online position verification protocol based on institution specific guidelines. Hereafter, surgical intervention will be performed to the standard of care.
Study: NCT06350838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG for Therapeutic Use
Description: Take 120 mg BCG for treatment, dissolved in 40 \~ 50 mL normal saline, bladder perfusion through catheter. The injection was performed once a week for 6 consecutive times.
Study: NCT05147272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-6306 (oral PKMYT1 inhibitor)
Description: RP-6306 in combination with gemcitabine
Study: NCT05217485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zio 14-day cardiac patch
Description: A wearble adhesive cardiac patch (14-day) called Zio
Study: NCT04918030

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: In-hospital staged PCI
Description: After revascularization of the culprit lesion, all significant non-culprit vessel will be complete revascularzed during index the index procedure (7±3 day).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Out-hospital staged PCI
Description: During the index procedure, patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 30±15 days to undergo PCI of the other significant coronary lesions.
Study: NCT05149222

Intervention type: DEVICE
Group type: OTHER
Intervention: Digital ACT
Description: This is a virtual, single-arm, non-significant risk study. Study participants will receive 9 months of Digital Acceptance and Commitment Therapy (ACT) in addition to their standard care for fibromyalgia.
Study: NCT05160961

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior plane block
Description: Serratus anterior plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
Study: NCT04605302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MCC/MCC-T
Description: Magnetically controlled capsule endoscopy (MCC), with or without tether, is used to visualize the upper gastrointestinal tract

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard gastroscopy
Description: Diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum
Study: NCT04857996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UBX1325
Description: Patients will be administered a single 50 μL UBX1325 IVT injection

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham procedure
Study: NCT04881071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scarf
Description: Scarf specifically designed to facilitate mother-neonate skin-to-skin contact

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual clinical practice
Description: Participants will receive the usual clinical practice
Study: NCT05704764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ending Self Stigma for Persons living with HIV and Use Substances
Description: Group-based intervention based on principles of cognitive behavioral therapy and social cognitive theory designed to reduce internalized stigma related to HIV and/or drug use.
Study: NCT06037733

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CTV omitted or delineated
Description: Patients who responded to the therapy (immunotherapy and chemotherapy) were randomly (1:1) assigned into CTV-omitted radiotherapy group or CTV-delineated radiotherapy group.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CTV omitted or delineated
Description: Patients who responded to the therapy (immunotherapy and chemotherapy) were randomly (1:1) assigned into CTV-omitted radiotherapy group or CTV-delineated radiotherapy group.
Study: NCT05796102

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET-MRI
Description: A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan. Magnetic Resonance Imaging (MRI) provides better soft tissue contrast compared to conventional computerized tomography (CT), and when combined with PET, can potentially provide better visualization of the tumor shape, size, and position.~Additional MRI imaging will be completed once during radiation treatment, and once after radiation treatment
Study: NCT04226690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active CBD/THC Dose 1
Description: Subjects will self-administer the assigned study medication daily at home after pickup and will be tested using medication compliance procedures. Subjects will visit the center 2 times in the 7-day period on days 1 and 7 for blood draws to assess medication compliance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active CBD/THC Dose 2
Description: Subjects will self-administer the assigned study medication daily at home after pickup and will be tested using medication compliance procedures. Subjects will visit the center 2 times in the 7-day period on days 1 and 7 for blood draws to assess medication compliance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matched placebo comparator
Description: Subjects will self-administer the assigned study medication daily at home after pickup and will be tested using medication compliance procedures. Subjects will visit the center 2 times in the 7-day period on days 1 and 7 for blood draws to assess medication compliance.
Study: NCT05261763

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: abc

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Dry Needing
Description: xyz
Study: NCT04885088

Intervention type: DEVICE
Intervention: Wisdom bracelet
Description: Wisdom bracelet

Intervention type: DEVICE
Intervention: Wisdom bracelet
Description: Wisdom bracelet
Study: NCT05897723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional Radiofrequency
Description: Fractional Radiofrequency (RF) delivering nano-fractional RF energy, causing fractional ablation and coagulation at the treatment site.
Study: NCT05592912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HydroLenz Injection
Description: The HydroLenz injection will be administered at the conclusion of the vitrectomy procedure on the operative day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HydroLenz Injection
Description: The HydroLenz injection will be administered at the conclusion of the vitrectomy procedure on the operative day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No HydroLenz Injection
Description: No HydroLenz injection will be administered at the conclusion of the vitrectomy procedure on the operative day.
Study: NCT04788251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise-based fall prevention intervention (Modified Otago Exercise Programme and Modified Stepping On Programme)
Description: The modified OEP is a group exercise programme that consists of progressive strength and balance exercises led by trained exercise leaders (fitness instructors or health coaches). The supervised sessions will be conducted twice a week (1 hour each) for 7 weeks. Participants will be given an exercise booklet and encouraged to exercise at home.~The modified SOP is a group fall prevention programme that consists of exercise sessions and discussions on various falls prevention aspects facilitated by a trained programme leader and supported by programme facilitators and peer facilitators. The supervised sessions will be conducted once a week (2 hours each) for 7 weeks. Participants will be given homework and encouraged to exercise at home. In addition, there will be an optional home visit (Week 11), a 1-hour booster session (Week 19) and a telephone call (Week 31).

Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list control
Description: To receive fall prevention resources while waiting for their programme to start
Study: NCT05651165

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacoactive balloon angioplasty. Lutonix®
Description: Percutaneous transluminal angioplasty with paclitaxel-coated balloon in the arteriosclerosis site to increase blood-flow to the distal arterial areas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mimetic stent.Supera®
Description: Multiple intertwined nitinol wires that provide greater radial resistance and allow for even stress distribution. Implanted through percutaneous transluminal angioplasty in the arteriosclerosis site to increase blood-flow to the distal arterial areas.
Study: NCT05316402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training on the risks associated with sun exposure
Description: 15-minute power point and presentation on the risks of sun exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dosimetry
Description: dosimetry